Apr. 7, 2014
WuXi PharmaTech received an international innovation award for its recently completed cGMP cell-culture-based biologics production facility, which is located in Wuxi City.
The award was created to showcase the best of each year’s new, state-of-the-art pharmaceutical manufacturing facilities. WuXi is the first company in China to receive this award. The judging panel praised WuXi’s “very innovative step” to adopt end-to-end single use technology at the plant. The facility’s design and construction are aligned with the most stringent expectations of Western biopharmaceutical manufacturers, the panel concluded. WuXi incorporated two parallel upstream cell culture bioreactor lines with flexible working volumes of 50L to 2,000L and one downstream purification production line into the plant. This arrangement gives WuXi the capacity, flexibility and quality to handle even the most demanding production projects. The facility is designed to meet cGMP standards of the U.S., the EU and China. It has been GMP-audited more than 10 times by global clients.